Skip to content
OpenCapital
Get started

Neurocrine Biosciences NBIX Q2 2025 earnings

Reported July 30, 2025 · After market close

Revenue$687.5MMiss by $58.9MDiluted EPS$1.06Beat by $0.08
Revenue estimate$746.4M
EPS estimate$0.98

Next report

Jul 30, 2026 (In 2 days)
Revenue estimate$890.0M
EPS estimate$1.64

Financials

Q2 2025

Income statement

See full
Revenue$687.5M+16.5%
Gross profit$676.2M+16.4%
Operating income$145.6M+0.1%
Net income$107.5M+65.4%
EPS (diluted)$1.06+68.3%

Balance sheet

See full
Cash & equivalents$272.0M+84.2%
Total debt$489.8M+68.0%
Total equity$2.7B+7.4%
Total assets$3.9B+17.7%

Cash flow

See full
Operating cash flow$102.0M+57.9%
CapEx$12.5M+7.8%
Free cash flow$89.5M+68.9%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$12.69B-7.7%
Enterprise value$12.9B-7.1%
P/E36.4×-4.1×
P/S5.1×-1.4×

Profitability

See full
Gross margin98.5%+0.2pp
Operating margin19.7%-5.6pp
Net margin13.9%-2.1pp
FCF margin21.1%-2.3pp

Returns & leverage

See full
Return on equity13.4%-2.2pp
Debt / equity0.2×+0.1×
Current ratio3.2×-1.0×

Segments

By segment

See full
Reportable Segment$687.5M+16.5%

By product

See full
Collaboration revenues$5.5M-14.1%

Versus estimates

Revenue

Q1 2026$814.5MBeat by $46.2MQ4 2025$805.5MBeat by $15.0MQ3 2025$794.9MMiss by $11.9M
Q2 2025$687.5MMiss by $58.9M
Q1 2025$572.6MBeat by $13.0MQ4 2024$627.7MMiss by $1.7M

Diluted EPS

Q1 2026$1.94Beat by $0.66Q4 2025$1.88Beat by $0.08Q3 2025$2.04Beat by $0.46
Q2 2025$1.06Beat by $0.08
Q1 2025$0.08Miss by $0.46Q4 2024$1.00Miss by $0.62

Ask the moment Neurocrine Biosciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Neurocrine Biosciences report Q2 2025 earnings?
Neurocrine Biosciences (NBIX) reported Q2 2025 earnings on July 30, 2025 after market close.
What were Neurocrine Biosciences's Q2 2025 revenue and EPS?
Neurocrine Biosciences reported revenue of $687.5M and diluted EPS of $1.06 for Q2 2025.
Did Neurocrine Biosciences beat estimates in Q2 2025?
Revenue missed the consensus estimate of $746.4M by $58.9M. EPS beat the consensus estimate of $0.98 by $0.08.
How did Neurocrine Biosciences's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.5% from $590.2M a year earlier and diluted EPS grew 68.3% from $0.63.
Where can I find Neurocrine Biosciences's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000914475-25-000158) directly on SEC EDGAR. The filing index links above go to sec.gov.